Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zai Lab Files to Raise $150 Million for Venture Fund

publication date: May 24, 2017
Shanghai's Zai Lab filed in the US to begin raising $150 million for its own venture fund. The company isn't talking about the fund yet, but its CEO, Samantha Du, PhD, is listed as the General Partner. Dr. Du has a high profile in China, having served as CEO of Hutchison MediPharma, partner at Sequoia Capital China, and since 2014, as Founder, Chairman and CEO of Zai Lab. In three years, Zai has in-licensed seven drug candidates from six companies. The official name of the fund is Zai Venture Fund I, suggesting venture capital could be an ongoing Zai activity. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital